West Pharmaceutical Services (WST) Receivables - Other (2023 - 2025)

West Pharmaceutical Services (WST) has reported Receivables - Other for 3 consecutive years, with $11.9 million the latest figure, recorded in Q4 2025.

• Quarterly Receivables - Other fell 48.93% year-over-year to $11.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $11.9 million (down 48.93% YoY) and the FY2025 annual result came in at $11.9 million, down 48.93% from the prior year.
• Receivables - Other eased to $11.9 million in Q4 2025 per WST's latest filing, from $23.3 million in the prior quarter.
• Over the last five years, Receivables - Other for WST reached as high as $23.3 million in Q4 2024 and fell as low as $11.9 million in Q4 2025.
• A 3-year average of $18.9 million and a median of $21.5 million in 2023 frame the typical range for Receivables - Other.
• Annual changes were most pronounced in 2024 — Receivables - Other advanced 8.37% — and 2025, when it sank 48.93%.
• Year by year, Receivables - Other stood at $21.5 million in 2023, then rose by 8.37% to $23.3 million in 2024, then plunged by 48.93% to $11.9 million in 2025.
• According to Business Quant data, Receivables - Other over the past three periods registered $11.9 million, $23.3 million, and $21.5 million for Q4 2025, Q4 2024, and Q4 2023 respectively.